MCID: SPN186
MIFTS: 61

Spinal Cord Injury

Categories: Bone diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Spinal Cord Injury

MalaCards integrated aliases for Spinal Cord Injury:

Name: Spinal Cord Injury 53 58 37 17
Spinal Cord Injuries 42

Characteristics:

Orphanet epidemiological data:

58
spinal cord injury
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 33 T09.3
UMLS via Orphanet 71 C0037929
Orphanet 58 ORPHA90058

Summaries for Spinal Cord Injury

MedlinePlus : 42 Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Spinal Cord Injury, also known as spinal cord injuries, is related to decubitus ulcer and acute cystitis. An important gene associated with Spinal Cord Injury is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are PEDF Induced Signaling and PAK Pathway. The drugs Acetylcholine and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are behavior/neurological and growth/size/body region

NINDS : 53 A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy axons -- extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis

Wikipedia : 73 A spinal cord injury (SCI) is damage to the spinal cord that causes temporary or permanent changes in... more...

Related Diseases for Spinal Cord Injury

Diseases related to Spinal Cord Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1030)
# Related Disease Score Top Affiliating Genes
1 decubitus ulcer 32.0 TNF MMP9 IL6
2 acute cystitis 31.6 TNF IL6 CXCL8
3 traumatic brain injury 31.5 IL6 GFAP CASP3 BDNF AQP4
4 constipation 31.4 NOS2 IL6 GDNF BDNF AQP4
5 mental depression 31.3 TNF IL6 BDNF
6 brain injury 31.3 IL6 GFAP CASP3 BDNF AQP4
7 hemorrhoid 31.0 TNF NOS2 MMP9
8 pain agnosia 31.0 TNF IL6 BDNF
9 sleep apnea 30.9 TNF IL6 CXCL8 BDNF
10 chronic ulcer of skin 30.9 TNF MMP9 IL6
11 intestinal obstruction 30.8 TNF IL6 GDNF
12 arachnoiditis 30.8 TNF AQP4
13 osteomyelitis 30.8 TNF IL6 CXCL8
14 pyelonephritis 30.8 TNF MMP9 IL6 CXCL8
15 spinal cord disease 30.7 TNF IL6 GFAP GDNF AQP4
16 pulmonary edema 30.6 TNF NOS2 CXCL8
17 cerebral palsy 30.6 TNF NOS2 IL6 CXCL8 BDNF
18 exanthem 30.6 TNF IL6 CXCL8
19 spinal disease 30.5 TNF IL6 GFAP CASP3
20 hydrocephalus 30.5 TNF GFAP CASP3 BDNF AQP4
21 neurotic disorder 30.5 TNF IL6 BDNF
22 severe acute respiratory syndrome 30.5 TNF IL6 CXCL8
23 prostatitis 30.4 TNF IL6 CXCL8 CASP3
24 sleep disorder 30.4 TNF IL6 CXCL8 BDNF
25 amyotrophic lateral sclerosis 1 30.4 TNF NGFR IL6 GFAP GDNF CASP3
26 aortic aneurysm, familial abdominal, 1 30.4 TNF MMP9 IL6 CXCL8
27 varicocele 30.4 TNF NOS2 IL6 CASP3
28 complex regional pain syndrome 30.4 TNF IL6 CXCL8
29 demyelinating disease 30.4 TNF MMP9 IL6 CSPG4 AQP4
30 brain edema 30.4 NOS2 MMP9 IL6 GFAP AQP4
31 myelitis 30.3 TNF MMP9 IL6 CXCL8 AQP4
32 bronchitis 30.3 TNF MMP9 IL6 CXCL8
33 pulmonary disease, chronic obstructive 30.3 TNF MMP9 IL6 CXCL8
34 vascular disease 30.3 TNF NOS2 MMP9 MAPK1 IL6 CASP3
35 internal hemorrhoid 30.3 NOS2 MMP9
36 cardiogenic shock 30.3 TNF IL6
37 transverse myelitis 30.3 TNF MMP9 IL6 CXCL8 AQP4
38 cerebral artery occlusion 30.3 TNF NOS2 GDNF BDNF AQP4
39 atherosclerosis susceptibility 30.3 TNF MMP9 IL6 CXCL8
40 neuroma 30.3 IL6 GFAP GDNF AQP4
41 proteasome-associated autoinflammatory syndrome 1 30.3 TNF NOS2 MMP9 IL6 CXCL8
42 asphyxia neonatorum 30.3 IL6 CASP3 BDNF
43 melancholia 30.2 TNF IL6 BDNF
44 mood disorder 30.2 NGFR MMP9 MAPK1 IL6 GFAP BDNF
45 cystitis 30.2 TNF NOS2 IL6 GDNF CXCL8 BDNF
46 endogenous depression 30.2 TNF IL6 BDNF
47 secondary progressive multiple sclerosis 30.2 MMP9 GDNF BDNF
48 arteriovenous malformation 30.2 TNF MMP9 IL6
49 primary progressive multiple sclerosis 30.2 TNF MMP9 BDNF
50 fasciitis 30.2 TNF IL6 GFAP CXCL8

Graphical network of the top 20 diseases related to Spinal Cord Injury:



Diseases related to Spinal Cord Injury

Symptoms & Phenotypes for Spinal Cord Injury

MGI Mouse Phenotypes related to Spinal Cord Injury:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 AQP4 BDNF CASP3 GDNF GFAP GJA1
2 growth/size/body region MP:0005378 10.45 AQP4 BDNF CASP3 CSPG4 GDNF GFAP
3 cellular MP:0005384 10.42 BDNF CASP3 CSPG4 GDNF GFAP GJA1
4 homeostasis/metabolism MP:0005376 10.41 AQP4 ARG1 BDNF CASP3 CSPG4 GFAP
5 cardiovascular system MP:0005385 10.4 AQP4 CASP3 GDNF GFAP GJA1 GRIN1
6 hematopoietic system MP:0005397 10.37 AQP4 ARG1 CASP3 CSPG4 GDNF GJA1
7 mortality/aging MP:0010768 10.36 AQP4 ARG1 BDNF CASP3 GDNF GFAP
8 immune system MP:0005387 10.34 AQP4 ARG1 CASP3 CSPG4 GDNF GFAP
9 nervous system MP:0003631 10.33 AQP4 ARG1 BDNF CASP3 CSPG4 GDNF
10 digestive/alimentary MP:0005381 10.31 AQP4 BDNF CASP3 GDNF GFAP IL6
11 endocrine/exocrine gland MP:0005379 10.21 AQP4 BDNF CASP3 GDNF GJA1 IL6
12 hearing/vestibular/ear MP:0005377 10.14 AQP4 BDNF CASP3 CSPG4 GJA1 GRIN1
13 integument MP:0010771 10.13 BDNF CASP3 GJA1 IL6 MAPK1 MMP9
14 muscle MP:0005369 10.13 CASP3 GDNF GFAP GJA1 IL6 MAPK1
15 no phenotypic analysis MP:0003012 9.97 AQP4 BDNF CASP3 CSPG4 GJA1 GRIN1
16 reproductive system MP:0005389 9.96 BDNF CASP3 GDNF GJA1 GRIN1 IL6
17 renal/urinary system MP:0005367 9.92 AQP4 CASP3 GDNF IL6 KLK8 MMP9
18 respiratory system MP:0005388 9.9 AQP4 BDNF CASP3 GJA1 GRIN1 IL6
19 vision/eye MP:0005391 9.4 AQP4 BDNF CASP3 GFAP GJA1 GRIN1
20 taste/olfaction MP:0005394 9.35 BDNF CASP3 GRIN1 MAPK1 NGFR

Drugs & Therapeutics for Spinal Cord Injury

Drugs for Spinal Cord Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 357)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Sodium citrate Approved, Investigational Phase 4 68-04-2
3
Amitriptyline Approved Phase 4 50-48-6 2160
4
Perphenazine Approved Phase 4 58-39-9 4748
5
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
6
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
7
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
8
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
9
Darifenacin Approved, Investigational Phase 4 133099-04-4 444031
10
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
11
Levetiracetam Approved Phase 4 102767-28-2 441341
12
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
13
Lactitol Approved, Investigational Phase 4 585-86-4 157355
14
Oxcarbazepine Approved Phase 4 28721-07-5 34312
15
Norepinephrine Approved Phase 4 51-41-2 439260
16
tannic acid Approved Phase 4 1401-55-4
17
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
18
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
19
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
20
Mecamylamine Approved, Investigational Phase 4 60-40-2 4032
21
Droxidopa Approved, Investigational Phase 4 23651-95-8 443940
22
Denosumab Approved Phase 4 615258-40-7
23
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
24
Baclofen Approved Phase 4 1134-47-0 2284
25
Zoledronic Acid Approved Phase 4 118072-93-8 68740
26
Cycloserine Approved Phase 4 68-41-7 401 6234
27
Glucagon Approved Phase 4 16941-32-5
28
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
29
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
30
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
31
Fidaxomicin Approved Phase 4 873857-62-6
32
Vancomycin Approved Phase 4 1404-90-6 14969 441141
33
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
35
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
36 Anesthetics Phase 4
37 Anesthetics, General Phase 4
38 Neurotransmitter Agents Phase 4
39 Venlafaxine Hydrochloride Phase 4
40 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
41 Hormones Phase 4
42 Calcium, Dietary Phase 4
43 Phosphodiesterase Inhibitors Phase 4
44 Anti-Arrhythmia Agents Phase 4
45 Sodium Channel Blockers Phase 4
46 Anesthetics, Local Phase 4
47 Diuretics, Potassium Sparing Phase 4
48 Cola Phase 4
49 abobotulinumtoxinA Phase 4
50 Muscarinic Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 1243)
# Name Status NCT ID Phase Drugs
1 The Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among Spinal Cord Injury Patients Who Have Yet to Develop Central Pain Unknown status NCT03748290 Phase 4 Pregabalin;Placebo Oral Tablet
2 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
3 An Open, Longitudinal, Prospective, Non-randomized, Self-Controlled Feasibility Study to Investigate the Effect of the ReWalk™ Device on Mobility Outcomes in Patients With Chronic Spinal Cord Injury. Unknown status NCT01943669 Phase 4
4 A Longitudinal Clinical Feasibility Study to Evaluate the Psychological and Functional Effects of Using the Tobii™ Eyegaze System by Inpatients With Tetraplegia Unknown status NCT01943656 Phase 4
5 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial Unknown status NCT03169582 Phase 4 Avanafil;Sildenafil
6 Assessment of Pregabalin Efficacy for the Treatment and Prevention of At-level Non-evoked and Evoked Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
7 Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
8 The Efficacy of Denosumab to Reduce Osteoporosis After Spinal Cord Injury Unknown status NCT01983475 Phase 4 Denosumab;Placebo (identical Denosumab volume of normal saline)
9 Early Nerve Reconstruction Approach in Tetraplegic Patients With Dysfunctional Upper Extremity: a Randomized Controlled Trial. Unknown status NCT01579604 Phase 4
10 A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study Completed NCT00592384 Phase 4 venlafaxine XR;placebo
11 Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in Spinal Cord Injury (SCI) Completed NCT04256603 Phase 4 Gabapentin
12 Bowel Care and Cardiovascular Function After Spinal Cord Injury Completed NCT01567605 Phase 4 Lidocaine lubricant
13 Melatonin Replacement for Treatment of Sleep Disruption Completed NCT00507546 Phase 4 Ramelteon;Placebo
14 Management of Chronic Pain in Rehabilitation Project I - Management of Chronic Pain in Persons With Spinal Cord Injury Completed NCT00006428 Phase 4 Amitriptyline
15 Botulinum Toxin A for the Treatment of Cervical/Shoulder Pain Following Acute Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
16 Omega-3 Supplementation to Increase HDL-c Levels in Those With Tetraplegia Completed NCT01896037 Phase 4
17 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed NCT00800462 Phase 4 Oxybutynin Cl;Trospium Cl;Darifenacin Hydrogen Bromide (HBr)
18 A Placebo-Controlled, Randomized, Two-Way Cross-Over, Double-Blind, Flexible Dose, Multicenter Study to Evaluate the Efficacy and Safety of Viagra in Male Patients With Traumatic Spinal Cord Injury and Erectile Dysfunction Completed NCT00654082 Phase 4 sildenafil;placebo
19 The Effect of Botulinum Toxin A in Post Spinal Cord Injury Neuropathic Pain Completed NCT01579500 Phase 4 Botulinum toxin type A;normal saline
20 Efficacy and Safety of Bowel Preparations for Colonoscopy in SCI Completed NCT00745095 Phase 4 Neostigmine
21 Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury - a Prospective, Randomized, Controlled, Multicentre Trial of Transanal Irrigation Vs. Conservative Bowel Management Completed NCT00286520 Phase 4
22 A Randomized, Double-blind, Placebo-controlled Cross-over Trial Assessing the Effect of Tadalafil (Cialis) on the Cardiovascular System in Men With Complete Spinal Cord Injury (SCI) at or Above the Sixth Thoracic Level Completed NCT01067391 Phase 4 tadalafil;placebo
23 A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury Completed NCT00224029 Phase 4 Oxybutynin transdermal system
24 Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury Completed NCT02298660 Phase 4 BOTOX
25 Effects of Levetiracetam on Chronic Neuropathic Pain Following Spinal Cord Injury: a Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Completed NCT00252954 Phase 4 Levetiracetam
26 Effect of PTH Combined With Weight-Bearing on Bone Density and Bone Architecture in People With Spinal Cord Injury Completed NCT00826228 Phase 4 teriparatide
27 The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury Completed NCT02042872 Phase 4 Zoledronic acid
28 Double-blind, Cross-over, Placebo Controlled Pilot Study to Characterize the Profile of Those Patients With Spinal Cord Injury Diagnosed by Electrophysiological, Urodynamic and Clinical (ASIA Group) Assessment Who May Respond to Vardenafil Treatment. (LEMDE) Completed NCT00667966 Phase 4 Vardenafil (Levitra, BAY 38-9456), 10 mg;Placebo;Vardenafil (Levitra, BAY 38-9456), 20 mg
29 A Six Month Randomized Open-Label Trial of Pressure Ulcer Healing With Microcyn® Skin and Wound Care With Preservatives Versus Sterile Saline in Adult Spinal Cord Injury Subjects Completed NCT02001558 Phase 4 Microcyn
30 Symptom-Based Treatment for Neuropathic Pain in Spinal Cord Injured Patients, Randomized Clinical Trial Completed NCT02180880 Phase 4 Pregabalin and Oxcarbazepine
31 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
32 Immunomodulation Therapy for Primary Prevention of Urinary Tract Infections in Patients With Spinal Cord Injury During First Rehabilitation: a Randomized Controlled Pilot Study Recruiting NCT04049994 Phase 4 Uro-Vaxom;Placebo oral tablet
33 An Open-label, Single Centre Prospective Cohort Study to Determine the Effectiveness and Safety of Targin® for Pain Management and Opioid-induced Constipation in Patients With Spinal Cord Injury: Can we Improve Pain and Ameliorate Secondary Complications of Opioid Treatment? Recruiting NCT03179475 Phase 4 Oxycodone Naloxone Combination
34 Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis Recruiting NCT03914677 Phase 4 Mecamylamine Oral Tablet
35 Utilizing Contrast-enhanced Ultrasound (CEUS) to Assess Critically Hypo Perfused Spinal Cord Tissue After Injury Recruiting NCT04056988 Phase 4 Perflutren Lipid Microsphere
36 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
37 The Efficacy of Denosumab to Prevent Bone Loss in Ambulatory and Non-ambulatory Motor-Incomplete Patients With Subacute Spinal Cord Injury Recruiting NCT03029442 Phase 4 Denosumab (Prolia)
38 Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury Recruiting NCT02922894 Phase 4 Trazodone;Placebo
39 Intrathecal (IT) Baclofen Drug Distribution Pilot Study Active, not recruiting NCT02903823 Phase 4 Baclofen bolus injection
40 Prevention of Bladder Dysfunction in Acute Spinal Cord Injury. A Double-blind, Randomized, Placebo-controlled Study to Explore the Effect of Early Treatment With Onabotulinumtoxin A on Development of Detrusor Overactivity Active, not recruiting NCT01698138 Phase 4 Onabotulinumtoxin A;Placebo
41 A Case Series of Patients With Spinal Cord Injury Treated With Standard Therapies and NeuroAiD Active, not recruiting NCT02537899 Phase 4 NeuroAiD
42 The Effect of an Oral Beta-2 Agonist on Respiratory Muscle Strength in SCI Active, not recruiting NCT02508311 Phase 4 Oral Albuterol Extended Release;Placebo
43 The Efficacy of a Once Weekly Glucagon-Like Peptide-1 Agonist on Body Weight/Composition and Metabolic Parameters in Persons With SCI Not yet recruiting NCT03292315 Phase 4 Exenatide 2 MG Injection [Bydureon]
44 Corticospinal Excitability of Leg Muscles After Spinal Cord Injury Not yet recruiting NCT02635893 Phase 4 D-Cycloserine;Placebo
45 Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density Not yet recruiting NCT04597931 Phase 4 Romosozumab;Zoledronic Acid
46 Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile Infection Terminated NCT02355938 Phase 4 Fidaxomicin 200 mg;Placebo;Vancomycin
47 Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured Terminated NCT00869427 Phase 4 vitamin C
48 Prospective, Non-randomized, Open-label, Mono-centric, Cohort Study on the Absorption of Oral Rivaroxaban in Patients With a Cervical Spinal Cord Injury Withdrawn NCT02970773 Phase 4 Rivaroxaban Oral Tablet
49 Zoledronic Acid to Prevent Bone Loss After Acute Spinal Cord Injury Unknown status NCT01642901 Phase 3 Zoledronic acid;normal saline 0.9%
50 Phase III Study of Minocycline in Acute Spinal Cord Injury Unknown status NCT01828203 Phase 3 Minocycline;Placebo

Search NIH Clinical Center for Spinal Cord Injury

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spinal Cord Injury cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spinal Cord Injury:
Adipose spheroid-derived Schwann cells for the treatment of spinal cord injury
Bone marrow-derived hematopoietic stem cells for spinal cord injury
Cerecellgram-Spine, bone marrow-derived mesenchymal stem cells for treatment of chronic spinal cord injury
GRNOPC1, hESC-derived oligodendrocyte progenitor cells for spinal cord injury
HuCNS-SC, human central nervous system stem cells for neurological diseases
MultiStem, bone marrow-derived cells for neurological disorders
NSI-566, spinal cord stem cells for neurological disorders
RNL-Astrostem, adipose-derived mesenchymal stem cells for treatment of spinal cord injury
Schwann cells for treatment of spinal cord injury
Umbilical cord-derived mesenchymal stem cells for treatment of spinal cord injury
Embryonic/Adult Cultured Cells Related to Spinal Cord Injury:
Schwann-like cells PMIDs: 20083105
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19364066
Bone marrow-derived mesenchymal stem cells
Oligodendrocyte progenitor-like cells PMIDs: 17253955 17996308
Human neural stem cells (HuCNS-SC) PMIDs: 16610769
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Fetal spinal cord stem cells (NSI-566) PMIDs: 22415942 19326469
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080 22017805
Schwann cells PMIDs: 23098734 23186720 16629629
Schwann cells PMIDs: 23098734 23186720 16629629
Umbilical cord-derived mesenchymal stem cells PMIDs: 23942181

Genetic Tests for Spinal Cord Injury

Anatomical Context for Spinal Cord Injury

MalaCards organs/tissues related to Spinal Cord Injury:

40
Spinal Cord, Bone Marrow, Bone, Brain, Cortex, Skeletal Muscle, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spinal Cord Injury:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
4 Peripheral Nervous System Peripheral Nerve Domain Myelinating Schwann Cells Potential therapeutic candidate
5 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
6 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
7 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
8 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Spinal Cord Injury

Articles related to Spinal Cord Injury:

(show top 50) (show all 33396)
# Title Authors PMID Year
1
Validation of Using Smartphone Built-In Accelerometers to Estimate the Active Energy Expenditures of Full-Time Manual Wheelchair Users with Spinal Cord Injury. 61 42
33671481 2021
2
COVID-19 and spinal cord injury and disease: results of an international survey as the pandemic progresses. 61 42
33579904 2021
3
Application and Reliability of Accelerometer-Based Arm Use Intensities in the Free-Living Environment for Manual Wheelchair Users and Able-Bodied Individuals. 42
33578639 2021
4
Differentially-expressed mRNAs, microRNAs and long noncoding RNAs in intervertebral disc degeneration identified by RNA-sequencing. 61
33764282 2021
5
Role of circular RNA expression in the pathological progression after spinal cord injury. 61
33642393 2021
6
Protein post-translational modifications after spinal cord injury. 61
33642363 2021
7
Delivery of pOXR1 through an injectable liposomal nanoparticle enhances spinal cord injury regeneration by alleviating oxidative stress. 61
33778197 2021
8
Fluoxetine, a selective serotonin reuptake inhibitor used clinically, improves bladder function in a mouse model of moderate spinal cord injury. 61
33642399 2021
9
Graphene oxide-composited chitosan scaffold contributes to functional recovery of injured spinal cord in rats. 61
33510090 2021
10
VX-765 reduces neuroinflammation after spinal cord injury in mice. 61
33510091 2021
11
High mobility group box 1 mediates inflammatory response of astrocytes via cyclooxygenase 2/prostaglandin E2 signaling following spinal cord injury. 61
33510092 2021
12
ISP and PAP4 peptides promote motor functional recovery after peripheral nerve injury. 61
33433490 2021
13
Hypoxia response element-directed expression of bFGF in dental pulp stem cells improve the hypoxic environment by targeting pericytes in SCI rats. 61
33553827 2021
14
A bioactive injectable self-healing anti-inflammatory hydrogel with ultralong extracellular vesicles release synergistically enhances motor functional recovery of spinal cord injury. 61
33615043 2021
15
Low-dose testosterone replacement therapy and electrically evoked resistance training enhance muscle quality after spinal cord injury. 61
33433474 2021
16
Induced pluripotent stem cell technology for spinal cord injury: a promising alternative therapy. 61
33433463 2021
17
Olfactory ensheathing cell transplantation alters the expression of chondroitin sulfate proteoglycans and promotes axonal regeneration after spinal cord injury. 61
33433495 2021
18
Cortical transcriptome analysis after spinal cord injury reveals the regenerative mechanism of central nervous system in CRMP2 knock-in mice. 61
33318403 2021
19
Utility of somatosensory and motor-evoked potentials in reflecting gross and fine motor functions after unilateral cervical spinal cord contusion injury. 61
33318412 2021
20
Neuroprotective effect of immunomodulatory peptides in rats with traumatic spinal cord injury. 61
33318405 2021
21
Ninjurin-1: a biomarker for reflecting the process of neuroinflammation after spinal cord injury. 61
33318413 2021
22
Identification of potential oxidative stress biomarkers for spinal cord injury in erythrocytes using mass spectrometry. 61
33318408 2021
23
Are mitochondria the key to reduce the age-dependent decline in axon growth after spinal cord injury? 61
33318447 2021
24
High flow or low flow? An unusual case of ischemic priapism following gunshot wound to the cervical spinal cord. 61
33747794 2021
25
Mesenchymal stem cell conditioned medium increases glial reactivity and decreases neuronal survival in spinal cord slice cultures. 61
33718633 2021
26
A new feasible approach based on utility of ninhydrin for selective fluorimetric analysis of baclofen. Application to content uniformity evaluation. 61
33140532 2021
27
Inhibition of ERK1/2 phosphorylation attenuates spinal cord injury induced astrocyte activation and inflammation through negatively regulating aquaporin-4 in rats. 61
33592275 2021
28
Surgical intervention combined with weight-bearing walking training improves neurological recoveries in 320 patients with clinically complete spinal cord injury: a prospective self-controlled study. 61
33229715 2021
29
Identification of four differentially expressed genes associated with acute and chronic spinal cord injury based on bioinformatics data. 61
33229721 2021
30
Knockdown of lncRNA SNHG14 alleviates LPS-induced inflammation and apoptosis of PC12 cells by regulating miR-181b-5p. 61
33791006 2021
31
Editorial Comment: Reasons for cessation of clean intermittent catheterization after spinal cord injury: Results from the Neurogenic Bladder Research Group spinal cord injury registry. 61
33621016 2021
32
Mash-1 modified neural stem cells transplantation promotes neural stem cells differentiation into neurons to further improve locomotor functional recovery in spinal cord injury rats. 61
33631250 2021
33
CCR2 downregulation attenuates spinal cord injury by suppressing inflammatory monocytes. 61
33098174 2021
34
Relationships between spinal cord blood flow measured with flow-sensitive alternating inversion recovery (FAIR) and neurobehavioral outcomes in rat spinal cord injury. 61
33556483 2021
35
The thrombin receptor links brain derived neurotrophic factor to neuron cholesterol production, resiliency and repair after spinal cord injury. 61
33549720 2021
36
Self-directed rehabilitation training intensity thresholds for efficient recovery of skilled forelimb function in rats with cervical spinal cord injury. 61
33290776 2021
37
Non-invasive approaches to functional recovery after spinal cord injury: Therapeutic targets and multimodal device interventions. 61
33453213 2021
38
Combining task-based rehabilitative training with PTEN inhibition promotes axon regeneration and upper extremity skilled motor function recovery after cervical spinal cord injury in adult mice. 61
33621609 2021
39
Promoting motor functions in a spinal cord injury model of rats using transplantation of differentiated human olfactory stem cells: A step towards future therapy. 61
33636233 2021
40
GSNOR and ALDH2 alleviate traumatic spinal cord injury. 61
33545099 2021
41
Bone marrow mesenchymal stem cell-derived exosomal microRNA-125a promotes M2 macrophage polarization in spinal cord injury by downregulating IRF5. 61
33609602 2021
42
Novel circular RNA 2960 contributes to secondary damage of spinal cord injury by sponging miRNA-124. 61
32918278 2021
43
Wearable robotic exoskeleton for gait reconstruction in patients with spinal cord injury: A literature review. 61
33717982 2021
44
Olfactory ensheathing cells seeded decellularized scaffold promotes axonal regeneration in spinal cord injury rats. 61
32720459 2021
45
Serotonergic innervation of respiratory motor nuclei after cervical spinal injury: Impact of intermittent hypoxia. 61
33460645 2021
46
Chiari 1: Is decompression always necessary previous to scoliosis surgery? 61
33792837 2021
47
Delayed-Onset Postoperative Paraplegia in Acute Type A Aortic Dissection. 61
32882192 2021
48
Interventions and cognitive functioning in adults with traumatic spinal cord injuries: a systematic review and meta-analysis. 61
31354083 2021
49
Beyond its anti-migraine properties, sumatriptan is an anti-inflammatory agent: A systematic review. 61
33792938 2021
50
Grape seed proanthocyanidins protect PC12 cells from hydrogen peroxide-induced damage via the PI3K/AKT signaling pathway. 61
33667598 2021

Variations for Spinal Cord Injury

Expression for Spinal Cord Injury

Search GEO for disease gene expression data for Spinal Cord Injury.

Pathways for Spinal Cord Injury

Pathways related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.67 TNF NOS2 NGFR MAPK1 IL6 GRIN1
2
Show member pathways
13.32 TNF NGFR MAPK1 IL6 CXCL8 CASP3
3
Show member pathways
13.32 TNF NOS2 MMP9 MAPK1 IL6 GRIN1
4
Show member pathways
13.2 TNF NOS2 MMP9 MAPK1 IL6 CXCL8
5
Show member pathways
13.01 TNF NGFR MAPK1 IL6 CASP3 BDNF
6
Show member pathways
12.87 TNF IL6 GDNF CXCL8 CASP3
7
Show member pathways
12.84 TNF MAPK1 IL6 GRIN1 CASP3
8
Show member pathways
12.84 TNF MAPK1 IL6 CXCL8 CASP3
9 12.84 NOS2 MMP9 MAPK1 IL6 CXCL8 CASP3
10 12.78 TNF NGFR MAPK1 CASP3 BDNF
11
Show member pathways
12.76 TNF MAPK1 IL6 CXCL8 CASP3
12
Show member pathways
12.74 TNF NOS2 MAPK1 IL6 CXCL8
13
Show member pathways
12.59 RTN4R NGFR MAPK1 BDNF
14 12.33 TNF MMP9 MAPK1 CASP3
15
Show member pathways
12.33 TNF NOS2 MAPK1 IL6 CXCL8
16 12.29 NGFR MMP9 IL6 CXCL8
17
Show member pathways
12.28 TNF MAPK1 IL6 CXCL8
18
Show member pathways
12.28 TNF NOS2 MAPK1 CASP3
19
Show member pathways
12.28 TNF NGFR IL6 CXCL8 BDNF
20 12.26 TNF MAPK1 IL6 CXCL8
21 12.26 TNF NOS2 MAPK1 IL6 CASP3
22
Show member pathways
12.24 TNF MMP9 MAPK1 IL6 CXCL8 CASP3
23
Show member pathways
12.2 TNF NOS2 IL6 CXCL8
24 12.15 TNF MAPK1 GRIN1 CASP3
25 12.1 TNF MAPK1 IL6 CXCL8
26 12.1 TNF NOS2 MMP9 MAPK1 IL6 CASP3
27 12.08 NGFR MAPK1 GRIN1 CASP3 BDNF
28 11.97 TNF NOS2 MMP9 IL6 CXCL8
29 11.94 TNF MMP9 MAPK1 IL6 CASP3
30 11.89 MAPK1 GJA1 CXCL8 CASP3
31 11.85 TNF MAPK1 IL6 CXCL8 CASP3
32
Show member pathways
11.83 MAPK1 CXCL8 CASP3
33
Show member pathways
11.82 TNF NGFR BDNF
34 11.82 MAPK1 IL6 CXCL8
35 11.81 GFAP GDNF CSPG4 BDNF
36 11.81 TNF NOS2 IL6 CXCL8 CASP3 ARG1
37
Show member pathways
11.78 TNF CXCL8 CASP3
38 11.77 TNF IL6 GRIN1 GJA1 CXCL8 CASP3
39 11.76 MMP9 MAPK1 CXCL8
40
Show member pathways
11.72 RTN4R NGFR CASP3 BDNF
41 11.71 TNF NOS2 IL6
42 11.71 NOS2 MMP9 MAPK1 CASP3
43 11.69 MMP9 IL6 CXCL8 CASP3
44
Show member pathways
11.67 NGFR MAPK1 BDNF
45 11.67 TNF MMP9 IL6 CXCL8
46 11.66 TNF RTN4R NOS2 NGFR MMP9 MAPK1
47 11.61 TNF NOS2 MAPK1 IL6 CXCL8 CASP3
48 11.6 TNF IL6 CXCL8 CASP3
49 11.57 TNF IL6 CXCL8
50 11.56 TNF IL6 CXCL8

GO Terms for Spinal Cord Injury

Cellular components related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 TNF MMP9 KLK8 IL6 GDNF CXCL8
2 membrane raft GO:0045121 9.46 TNF RTN4R GJA1 CASP3
3 extracellular region GO:0005576 9.4 TNF NGFR MMP9 MAPK1 KLK8 IL6
4 astrocyte end-foot GO:0097450 8.96 GFAP AQP4

Biological processes related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.01 NGFR MMP9 IL6 GDNF CASP3
2 positive regulation of gene expression GO:0010628 9.98 TNF MAPK1 IL6 GJA1 CXCL8
3 axon guidance GO:0007411 9.88 NGFR MAPK1 GDNF BDNF
4 positive regulation of apoptotic process GO:0043065 9.83 TNF NGFR MMP9 IL6 CASP3
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 TNF IL6 BDNF
6 regulation of insulin secretion GO:0050796 9.74 TNF NOS2 IL6
7 neuron projection morphogenesis GO:0048812 9.71 KLK8 GJA1 BDNF
8 response to glucocorticoid GO:0051384 9.7 TNF IL6 CASP3
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.63 TNF MMP9 GJA1
10 positive regulation of neuroinflammatory response GO:0150078 9.61 TNF IL6
11 regulation of neuroinflammatory response GO:0150077 9.6 MMP9 IL6
12 negative regulation of axon regeneration GO:0048681 9.59 RTN4R KLK8
13 cellular response to amyloid-beta GO:1904646 9.58 NGFR GRIN1 GJA1
14 Bergmann glial cell differentiation GO:0060020 9.56 MAPK1 GFAP
15 response to wounding GO:0009611 9.56 KLK8 GFAP CASP3 ARG1
16 negative regulation of lipid storage GO:0010888 9.55 TNF IL6
17 response to lipopolysaccharide GO:0032496 9.55 NOS2 MAPK1 GJA1 CASP3 ARG1
18 neurotrophin TRK receptor signaling pathway GO:0048011 9.54 NGFR CASP3 BDNF
19 positive regulation of receptor binding GO:1900122 9.51 MMP9 BDNF
20 positive regulation of glial cell proliferation GO:0060252 9.5 TNF IL6 GFAP
21 vascular endothelial growth factor production GO:0010573 9.49 TNF IL6
22 arginine catabolic process GO:0006527 9.48 NOS2 ARG1
23 cellular response to lipopolysaccharide GO:0071222 9.35 TNF NOS2 IL6 CXCL8 ARG1
24 cytokine-mediated signaling pathway GO:0019221 9.1 TNF NOS2 MMP9 IL6 CXCL8 CASP3

Sources for Spinal Cord Injury

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....